These NBA players have reliable upside that can be leveraged for your DFS lineups on NBA's opening night doubleheader.

Adjuvant treatment with alectinib (Alecensa) yielded a 4-year overall survival (OS) rate of 98.4% in patients with resected, ALK mutation-positive, early stage non–small cell lung cancer (NSCLC), ...

Despite the surge in incidents, the department confirmed that no major accidents or casualties occurred during the ...

Dean’s Future Scholars (DFS), housed in the College of Education & Human Development at the University of Nevada, Reno, ...

Atezolizumab improved DFS and OS in ctDNA-positive MIBC patients, with a median DFS of 9.9 months vs 4.8 months for placebo. Serial ctDNA testing may offer a more accurate assessment of MRD and early ...

Brandon's DraftKings and FanDuel UCL DFS lineup picks for UEFA Champions League Soccer on 10/21/25 (Matchweek 3, Day One). His top daily fantasy soccer forwards, midfielders, defenders, goalkeepers.

This extremely talented young player keeps contending in the fall, and our DFS expert expects that to continue ...

It’s Tuesday, October 21st. The National Basketball Association (NBA) has a pair of Opening Night games on the schedule. The ...

Natera has announced positive results from the Phase III IMvigor011 clinical trial for muscle-invasive bladder cancer (MIBC).

Tuesday is the biggest day of the week for the NHL, and today's slate doesn't look like it will disappoint. There are 10 ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 ...

In MIBC patients, ctDNA-guided, adjuvant atezolizumab treatment is associated with significant survival improvements over placebo.